Vitrolife (VITR) 주식 개요
Vitrolife AB(publ)는 유럽, 중동, 아프리카, 아시아 태평양 및 미주 지역에서 보조 생식 제품을 제공합니다. 자세히 보기
VITR Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vitrolife AB (publ) 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | SEK 96.55 |
| 52주 최고가 | SEK 153.50 |
| 52주 최저가 | SEK 84.60 |
| 베타 | 1.72 |
| 1개월 변동 | 5.06% |
| 3개월 변동 | -10.68% |
| 1년 변동 | -32.01% |
| 3년 변동 | -40.98% |
| 5년 변동 | -78.85% |
| IPO 이후 변동 | 1,259.86% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jul 14
VITR: Leadership Transition And Bearish Research Will Set Up Future Re-Rating Potential
Analysts have trimmed their fair value estimate for Vitrolife from SEK162.75 to SEK130.20, citing a slightly higher discount rate, modest adjustments to revenue growth and profit margin assumptions, and more conservative future P/E expectations following recent bearish research and a downgrade. What’s in the News for Vitrolife Vitrolife announced that CEO Bronwyn Brophy O'Connor has resigned to take a CEO role in another part of the medtech industry.
내러티브 업데이트 • Jun 30
VITR: Higher Discount Rate Reset Will Likely Unlock Future Upside
The Vitrolife analyst price target has been trimmed from SEK 230 to SEK 215, as analysts cite a higher required discount rate and a lower assumed future P/E multiple following more cautious research, including a downgrade from Pareto. What’s in the News for Vitrolife Vitrolife AB (publ) announced that CEO Bronwyn Brophy O'Connor has decided to leave the company to take a CEO role elsewhere in the medtech industry.내러티브 업데이트 • Jun 16
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price expectations for Vitrolife, with the consensus target moving slightly lower to SEK 162.75 as some now see a more cautious outlook following recent downgrades. Key valuation inputs such as the discount rate and assumed future P/E have been adjusted only marginally.내러티브 업데이트 • Jun 01
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price target on Vitrolife to SEK162.75 from SEK172.20, citing slightly higher discount rate assumptions, more cautious revenue growth expectations, softer profit margin estimates, and a modestly lower future P/E multiple following recent bearish Street research, including a downgrade from Pareto. What's in the News CEO Bronwyn Brophy O'Connor has resigned to take a CEO role elsewhere in the medtech industry, and the Board has started a recruitment process for a new CEO.Recent updates
내러티브 업데이트 • Jul 14
VITR: Leadership Transition And Bearish Research Will Set Up Future Re-Rating Potential
Analysts have trimmed their fair value estimate for Vitrolife from SEK162.75 to SEK130.20, citing a slightly higher discount rate, modest adjustments to revenue growth and profit margin assumptions, and more conservative future P/E expectations following recent bearish research and a downgrade. What’s in the News for Vitrolife Vitrolife announced that CEO Bronwyn Brophy O'Connor has resigned to take a CEO role in another part of the medtech industry.내러티브 업데이트 • Jun 30
VITR: Higher Discount Rate Reset Will Likely Unlock Future Upside
The Vitrolife analyst price target has been trimmed from SEK 230 to SEK 215, as analysts cite a higher required discount rate and a lower assumed future P/E multiple following more cautious research, including a downgrade from Pareto. What’s in the News for Vitrolife Vitrolife AB (publ) announced that CEO Bronwyn Brophy O'Connor has decided to leave the company to take a CEO role elsewhere in the medtech industry.내러티브 업데이트 • Jun 16
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price expectations for Vitrolife, with the consensus target moving slightly lower to SEK 162.75 as some now see a more cautious outlook following recent downgrades. Key valuation inputs such as the discount rate and assumed future P/E have been adjusted only marginally.내러티브 업데이트 • Jun 01
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price target on Vitrolife to SEK162.75 from SEK172.20, citing slightly higher discount rate assumptions, more cautious revenue growth expectations, softer profit margin estimates, and a modestly lower future P/E multiple following recent bearish Street research, including a downgrade from Pareto. What's in the News CEO Bronwyn Brophy O'Connor has resigned to take a CEO role elsewhere in the medtech industry, and the Board has started a recruitment process for a new CEO.내러티브 업데이트 • May 12
VITR: Governance Reforms And Higher P/E Expectations Will Support Future Upside Potential
Vitrolife's analyst price target has been adjusted from SEK 162.67 to SEK 172.20. Analysts point to modest tweaks in fair value assumptions, discount rate, revenue growth, profit margin and future P/E forecasts, even as some research houses, such as Pareto, have turned more cautious on the stock.내러티브 업데이트 • Apr 27
VITR: Governance Reforms And Reset Expectations Will Support Future Upside Potential
Vitrolife’s analyst price target has been trimmed slightly from SEK 163.40 to about SEK 162.70, as analysts factor in updated assumptions on growth, margins and future P/E, and reflect the more cautious tone seen in recent research such as Pareto’s downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the revised target near SEK 162.70 as still implying upside relative to where caution has already been factored into growth, margin and P/E assumptions.내러티브 업데이트 • Apr 12
VITR: Governance Amendments And Steady Assumptions Will Support Future Upside
Analysts have reduced their price target for Vitrolife to SEK 163.40 from SEK 176.75, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News Vitrolife AB (publ) has proposed amendments to its Articles of Association to be decided at the Annual General Meeting scheduled for May 5, 2026.내러티브 업데이트 • Mar 29
VITR: Stable Fair Value And Tweaked Assumptions Will Support Future Upside
Analysts have kept Vitrolife's fair value estimate broadly unchanged at SEK 176.75, with only minor tweaks to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, which has driven a very small adjustment to their price target framework. Valuation Changes Fair Value Estimate was kept stable at SEK 176.75, indicating no change in the central valuation outcome.내러티브 업데이트 • Mar 13
VITR: Genetic Services Restructuring And Impairment Will Underpin Future Upside Potential
Analysts have kept their SEK 176.75 price target for Vitrolife broadly unchanged, making only very small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions to reflect fine tuning in their models rather than a shift in their overall view. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, tied to the Igenomix acquisition (company announcement).내러티브 업데이트 • Feb 26
VITR: Genetic Services Restructuring And Impairment Will Support Future Upside Potential
Analysts have left their SEK 176.75 price target for Vitrolife unchanged, with only minimal tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (company announcement).내러티브 업데이트 • Feb 11
VITR: Restructuring Of Genetic Services Will Drive Future Upside Potential
Analysts have trimmed their price target on Vitrolife to €176.75 from €187, reflecting updated assumptions that include a higher discount rate, a higher future P/E multiple, and revised expectations for revenue growth and profit margins. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (Key Developments).내러티브 업데이트 • Jan 27
VITR: Restructuring And Goodwill Impairment Will Drive Future Upside Potential
Analysts have trimmed their price target on Vitrolife from SEK188.75 to SEK187.00, reflecting adjustments to revenue growth and discount rate assumptions, along with updated views on profit margin and future P/E levels. What's in the News Vitrolife plans a restructuring program for its genetic services business, targeting annualised savings of SEK 65 million.내러티브 업데이트 • Jan 10
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Analysts have maintained their fair value estimate for Vitrolife at SEK 188.75, with only minor technical adjustments to the discount rate and future P/E assumptions shaping the updated price target narrative. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, related to the Igenomix acquisition (company announcement).내러티브 업데이트 • Dec 25
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Analysts have slightly reduced their price target on Vitrolife, trimming fair value by SEK 4.75 to SEK 188.75, as modestly higher long term growth assumptions are offset by a small downgrade to profitability and a lower expected valuation multiple. What's in the News Vitrolife plans to record a SEK 5.4 billion goodwill impairment in the fourth quarter of 2025 related to the Igenomix acquisition (company announcement).분석 기사 • Dec 18
There's No Escaping Vitrolife AB (publ)'s (STO:VITR) Muted Revenues
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a buy right now...내러티브 업데이트 • Dec 11
VITR: Higher Long Term Revenue Outlook Will Support Further Upside
Analysts have nudged their price target on Vitrolife slightly higher to SEK 193.50 from SEK 193.00, citing marginally stronger long term revenue growth expectations that more than offset a modest uptick in the assumed discount rate and a slightly lower forecast profit margin. Valuation Changes Fair Value Estimate: unchanged at SEK 193.5 per share, indicating no revision to the intrinsic value despite minor model adjustments.내러티브 업데이트 • Nov 27
VITR: Current Metrics And Stable Margins Will Support Further Upside
Analysts have maintained their fair value price target for Vitrolife at SEK 193.50, citing steady expectations for the company's growth, profitability, and valuation metrics. Valuation Changes Consensus Analyst Price Target: Unchanged at SEK 193.50.분석 기사 • Nov 26
Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...내러티브 업데이트 • Nov 11
VITR: Stable Profitability And Marginal Rate Shift Will Drive Future Upside
Narrative Update on Vitrolife Analyst Price Target Vitrolife's analyst price target remains unchanged at SEK 193.50. Analysts cite only minor adjustments in growth and profitability forecasts, affirming their previous valuation stance.내러티브 업데이트 • Oct 28
Profit Margins And Revenue Outlook Will Support Recovery Trends Ahead
Narrative Update on Vitrolife Analyst Price Target Analysts have raised Vitrolife’s fair value estimate from SEK191.75 to SEK193.50. They highlight the company's improved profit margin outlook and stronger projected revenue growth as key drivers behind the revised target.분석 기사 • Oct 28
Vitrolife AB (publ) (STO:VITR) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Investors in Vitrolife AB (publ) ( STO:VITR ) had a good week, as its shares rose 6.6% to close at kr151 following the...내러티브 업데이트 • Oct 14
US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery
Analysts have lowered their price target for Vitrolife from SEK 202.50 to SEK 191.75. This reflects updated expectations for slower revenue growth and profit margins, as well as a slightly higher discount rate.분석 기사 • Aug 25
Vitrolife AB (publ)'s (STO:VITR) Shares Lagging The Industry But So Is The Business
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.3x might make it look like a strong buy right...새로운 내러티브 • Jul 28
US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery
Recovery in IVF procedure volume and expansion in key regions will drive organic revenue growth and margin improvement as market conditions stabilize.분석 기사 • Jul 08
Vitrolife AB (publ)'s (STO:VITR) Intrinsic Value Is Potentially 68% Above Its Share Price
Key Insights Vitrolife's estimated fair value is kr242 based on 2 Stage Free Cash Flow to Equity Current share price of...분석 기사 • Jun 20
Here's Why Vitrolife (STO:VITR) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Apr 25
Vitrolife AB (publ)'s (STO:VITR) Price Is Right But Growth Is Lacking
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.4x might make it look like a buy right now...분석 기사 • Mar 13
Here's Why Vitrolife (STO:VITR) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Feb 20
Estimating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Vitrolife's estimated fair value is kr216 based on 2 Stage Free Cash Flow to Equity Vitrolife's kr213...분석 기사 • Nov 27
Is Vitrolife (STO:VITR) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Aug 21
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr204 Current share price of...분석 기사 • Jul 20
Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next
Vitrolife AB (publ) ( STO:VITR ) just released its quarterly report and things are looking bullish. Vitrolife beat...분석 기사 • Jul 18
Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth
The Vitrolife AB (publ) ( STO:VITR ) share price has done very well over the last month, posting an excellent gain of...분석 기사 • Apr 03
Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Mar 07
A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr215 With kr186 share price...분석 기사 • Feb 05
Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now
The yearly results for Vitrolife AB (publ) ( STO:VITR ) were released last week, making it a good time to revisit its...분석 기사 • Jan 05
Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 62.5x Vitrolife AB (publ) ( STO:VITR ) may be sending very bearish signals...분석 기사 • Dec 15
Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • Nov 27
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Vitrolife's estimated fair value is kr193 based on 2 Stage Free Cash Flow to Equity With kr173 share...분석 기사 • Nov 06
Is Vitrolife (STO:VITR) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...주주 수익률
| VITR | SE Biotechs | SE 시장 | |
|---|---|---|---|
| 7D | 11.7% | -3.3% | 1.3% |
| 1Y | -32.0% | 22.4% | 11.2% |
수익률 대 산업: VITR은 지난 1년 동안 22.4%의 수익을 기록한 Swedish Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: VITR은 지난 1년 동안 11.2%를 기록한 Swedish 시장보다 저조한 성과를 냈습니다.
주가 변동성
| VITR volatility | |
|---|---|
| VITR Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.4% |
| 10% least volatile stocks in SE Market | 3.5% |
안정적인 주가: VITR는 지난 3개월 동안 Swedish 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: VITR의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1989 | 1,126 | Bronwyn Brophy O´Connor | www.vitrolife.com |
Vitrolife AB(publ)는 유럽, 중동, 아프리카, 아시아 태평양 및 미주 지역에서 보조 생식술 제품을 제공합니다. 정자 처리, 난자 채취 바늘, 미세 조작 피펫, 타임랩스 시스템 및 평가 도구, 레이저 및 이미징 시스템, 시험관 아기 배지 및 오일, 배아 이식, 냉동 보존, 유전체학 키트 등을 제공합니다. 이 회사는 또한 접시, 피펫, 튜브, VitroTemp와 같은 eWitness 및 Labware 제품도 제공합니다.
Vitrolife AB (publ) 기초 지표 요약
| VITR 기초 통계 | |
|---|---|
| 시가총액 | SEK 11.82b |
| 순이익 (TTM) | -SEK 5.01b |
| 매출 (TTM) | SEK 3.41b |
3.8x
주가매출비율(P/S)-2.6x
주가수익비율(P/E)VITR는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| VITR 손익계산서 (TTM) | |
|---|---|
| 매출 | SEK 3.41b |
| 매출원가 | SEK 1.41b |
| 총이익 | SEK 2.00b |
| 기타 비용 | SEK 7.01b |
| 순이익 | -SEK 5.01b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Oct 22, 2026
| 주당순이익(EPS) | -37.00 |
| 총이익률 | 58.65% |
| 순이익률 | -147.17% |
| 부채/자본 비율 | 18.0% |
VITR의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
1.1%
현재 배당 수익률-3%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/16 17:23 |
| 종가 | 2026/07/16 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Vitrolife AB (publ)는 11명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | ABG Sundal Collier |
| Kallum Titchmarsh | BofA Global Research |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |